Intermediate for Tofacitinib. Tofacitinib (trade name Xeljanz, Jakvinus) is a janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib has been approved by the U.S Food and Drug Administration in November 2012.
Product Name: (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine bis-(hydrochloride)
CAS Number: 1062580-52-2
Molecular Weight:  291.263
Molecular Formula:  C14H24Cl2N2
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.